Scholars Central

Conference abstractPublished 3 Jul 2013

Therapeutic Drug Monitoring of Anti-Retroviral Drugs

Authors: Bhaswat S. Chakraborty

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Most current highly active antiretroviral therapy (HAART) regimens for HIV- positive patients contain two nucleoside reverse transcriptase inhibitors (NRTIs) with either a Protease inhibitor (PIs) or a non-nucleoside reverse transcriptase inhibitors (NNRTI). Notwithstanding the regulatory guidelines recommending therapeutic drug monitoring (TDM) for these drugs, therapeutic failure is a very serious concern implying drug induced toxicity and more importantly viral rebound and viral resistance. Single dose, steady state and dose ranging studies have all more or less demonstrated that there is a positive correlation between plasma concentrations and therapeutic effects of anti-retrovirals (ARVs). However, one of the main challenges still seems to be the target concentrations for these drugs and their relevant inhibitory quotient. In this talk, we are going to examine these issues along with bioanalytical challenges, drug-effect and drug�toxicity relationships and finally drug-drug interactions within different HAART regimes.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Analytical & Bioanalytical Techniques.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Analytical & Bioanalytical Techniques
  • SubjectBiochemistry & Biotechnology
  • SubjectChemistry
  • BylineArticles whose byline prints “Bhaswat S. Chakraborty”